Immunovia
Egetis attracts a bid and agrees to sell its priority review voucher, Lytix meets its endpoint in melanoma and Novo raises its outlook – the Nordic Pulse | 2026:45
Xbrane clears the FDA, BioInvent seeks 430 Mkr and Genmab keeps surging – the Nordic Pulse | 2026:44
Analytics
Zealand wins in obesity, Genmab hits first-line DLBCL and Oncopeptides crosses the blood-brain barrier – the Nordic Pulse | 2026:41
Egetis wins FDA approval, Indices retreat across the board – the Nordic Pulse | 2026:40
A quarter of billion-euro licences, a Novo comeback and a flat Nordic index – the State of Nordic BioPharma | 2026:Q3
Analytics
Novo raises outlook, BioInvent breaks through, Nordics tread water – the Nordic Pulse | 2026:32
Immunovia inleder lansering i Kalifornien efter godkännande
Immunovias CLARITI-studie publicerad i Gastroenterology
Immunovia rapporterar valideringsresultat för PancreaSure
Immunovia säkrar kontroll över PancreaSure-testets leverantörskedja
Immunovia ingår samarbete med Inova Schar Cancer
Immunovia får preliminär ersättning för PancreaSure-test
MARKET SIGNAL
Dagens nyhetssvep
Nyhetssvepet tisdag 17 november
NYHETSBREV
ANALYTICS
Analysts raise Novo price target after Q3 report
Oncopeptides, Novo and Zealand clear the European Commission while Cereno plunges on rights issue – the Nordic Pulse | 2026:46
Nine of ten AstraZeneca analyst houses raised their targets after Q3
Kommande event
MedTech Summit 2027
After a phenomenal debut last year, the premier gathering for medical technology is officially back. The response to our inaugural...
Global Forum 2027
Global Forum Returns for its 4th Edition. The premier networking event for Nordic life science companies, investors, and industry experts...
Investor Cardiometabolic Day
An exclusive boutique event in Copenhagen dedicated entirely to investors, C-level executives, and key leaders working within the cardiometabolic field....
Rekommenderat
Oncopeptides om EU-godkännandet som flyttar Pepaxti till tredje linjen
Rekordförsäljning för RaySearch men marginalen pressas
Xbrane om FDA-godkännandet som öppnar USA för Lucamzi
Hansa om IND-ansökan för HNSA-5487 och utvalda PAES-resultat
AcuCort ur startblocken – siktar mot USA och svarta siffror
Du är värd det bästa!
Lås upp vårt premium-innehåll: Bli prenumerant!
Skapa konto